Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111748 · ClinicalTrials.gov registry record · Phase 3
UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
A Phase 3 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT00111748 is a Phase 3 study that has completed, run by University of Arkansas. The registered enrollment target is 180 participants.
The verdict
NCT00111748, a Phase 3 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
The main goal of this study is to evaluate the effectiveness of the combination of these drugs, and whether they can be given safely together.
Interventions
- DRUG Velcade, Thalidomide, Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111748
The ClinicalTrials.gov registry entry for NCT00111748 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Velcade, Thalidomide, Dexamethasone is the first listed.
NCT00111748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111748 about?
NCT00111748 is a clinical study titled "UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients". The main goal of this study is to evaluate the effectiveness of the combination of these drugs, and whether they can be given safely together.
What is the current status of trial NCT00111748?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2005-02. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00111748?
The interventions under investigation include: Velcade, Thalidomide, Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00111748?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.